INTRODUCTION: Although there is a lack of established survival benefit of sentinel lymph node biopsy (SLNB), this technique has been increasingly applied in the staging of patients with thin (≤1.00 mm) melanoma (T1Nx), without clear supportive evidence. METHODS: We review the guidelines and available literature on the indications and rationale for performing SLNB in thin melanoma. RESULTS: As a consequence of the paucity of evidence of SLNB in thin melanoma, there is considerable variability in the guidelines. It is difficult to define clinicopathologic factors that reliably predict the presence of nodal metastasis. SLNB does not yet inform management in thin melanoma to improve survival outcome. CONCLUSION: Based on available evidence, high risk patients with melanomas between 0.75 and 1.00 mm may be appropriate candidates to be considered for SLN biopsy after discussing the likelihood of finding evidence of nodal progression, the risks of sentinel node biopsy, and the lack of proven survival benefit from any form of surgical nodal staging.
INTRODUCTION: Although there is a lack of established survival benefit of sentinel lymph node biopsy (SLNB), this technique has been increasingly applied in the staging of patients with thin (≤1.00 mm) melanoma (T1Nx), without clear supportive evidence. METHODS: We review the guidelines and available literature on the indications and rationale for performing SLNB in thin melanoma. RESULTS: As a consequence of the paucity of evidence of SLNB in thin melanoma, there is considerable variability in the guidelines. It is difficult to define clinicopathologic factors that reliably predict the presence of nodal metastasis. SLNB does not yet inform management in thin melanoma to improve survival outcome. CONCLUSION: Based on available evidence, high risk patients with melanomas between 0.75 and 1.00 mm may be appropriate candidates to be considered for SLN biopsy after discussing the likelihood of finding evidence of nodal progression, the risks of sentinel node biopsy, and the lack of proven survival benefit from any form of surgical nodal staging.
Authors: Ullrich Krüger; Lutz Kretschmer; Kai-Martin Thoms; Michael Padeken; Hans Peter Bertsch; Michael P Schön; Markus Zutt Journal: Melanoma Res Date: 2011-10 Impact factor: 3.599
Authors: Zbigniew I Nowecki; Piotr Rutkowski; Anna Nasierowska-Guttmejer; Wlodzimierz Ruka Journal: Ann Surg Oncol Date: 2006-10-03 Impact factor: 5.344
Authors: K M McMasters; D S Reintgen; M I Ross; J E Gershenwald; M J Edwards; A Sober; N Fenske; F Glass; C M Balch; D G Coit Journal: J Clin Oncol Date: 2001-06-01 Impact factor: 44.544
Authors: Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245
Authors: R S Oliveira Filho; L M Ferreira; L J Biasi; M M S S Enokihara; G R Paiva; J Wagner Journal: Braz J Med Biol Res Date: 2003-03-07 Impact factor: 2.590
Authors: J E Gershenwald; M I Colome; J E Lee; P F Mansfield; C Tseng; J J Lee; C M Balch; M I Ross Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: Dale Han; Jonathan S Zager; Yu Shyr; Heidi Chen; Lynne D Berry; Sanjana Iyengar; Mia Djulbegovic; Jaimie L Weber; Suroosh S Marzban; Vernon K Sondak; Jane L Messina; John T Vetto; Richard L White; Barbara Pockaj; Nicola Mozzillo; Kim James Charney; Eli Avisar; Robert Krouse; Mohammed Kashani-Sabet; Stanley P Leong Journal: J Clin Oncol Date: 2013-11-04 Impact factor: 44.544
Authors: Antonio Tejera-Vaquerizo; Simone Ribero; Susana Puig; Aram Boada; Sabela Paradela; David Moreno-Ramírez; Javier Cañueto; Blanca de Unamuno; Ana Brinca; Miguel A Descalzo-Gallego; Simona Osella-Abate; Paola Cassoni; Cristina Carrera; Sergi Vidal-Sicart; Antoni Bennássar; Ramón Rull; Llucìa Alos; Celia Requena; Isidro Bolumar; Víctor Traves; Ángel Pla; A Fernández-Orland; Ane Jaka; María T Fernández-Figueres; Josep M Hilari; Pol Giménez-Xavier; Ricardo Vieira; Rafael Botella-Estrada; Concepción Román-Curto; Lara Ferrándiz; Nicolás Iglesias-Pena; Carlos Ferrándiz; Josep Malvehy; Pietro Quaglino; Eduardo Nagore Journal: Cancer Med Date: 2019-06-18 Impact factor: 4.452
Authors: A Kocsis; L Karsko; Zs Kurgyis; Zs Besenyi; L Pavics; E Dosa-Racz; E Kis; E Baltas; H Ocsai; E Varga; B Bende; A Varga; G Mohos; I Korom; J Varga; L Kemeny; I B Nemeth; J Olah Journal: Pathol Oncol Res Date: 2019-12-02 Impact factor: 3.201